FOAMIX PHARMACEUTICALS LTD. (NASDAQ:FOMX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition
On November 7, 2018, Foamix Pharmaceuticals Ltd. (the “Company”) issued a press release announcing its financial results for its third quarter ended September 30, 2018. A copy of the press release is furnished as Exhibit 99.1 hereto.
The information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure
The Company announced positive topline results from the Company’s Phase III clinical trial of its FMX103 topical minocycline foam for the treatment of moderate-to-severe papulopustular rosacea on Wednesday, November 7, 2018. A copy of the slides presented during the webcast are available on the Company’s website, and are being furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information disclosed under this Item 7.01, including Exhibit 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events
On November 7, 2018, the Company issued a press releaseannouncing positive topline results from the FMX103 clinical trial. A copy of the press release is filed herewith as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Foamix Pharmaceuticals Ltd. ExhibitEX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update Conference Call and Webcast Thursday,…To view the full exhibit click here
About FOAMIX PHARMACEUTICALS LTD. (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations. The Company develops FMX101, FMX102, FMX103 and FDX104 using its technology, which includes foam-based platforms. The Company’s lead product candidate FMX101, is a novel topical foam formulation of the antibiotic minocycline. The Company develops FMX102, a minocycline foam product candidate for the treatment of impetigo, including cases of impetigo caused by methicillin-resistant staphylococcus aureus (MRSA). It is also developing FMX103, minocycline foam for rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It completed a Phase II clinical trial for FMX102.